Sign in

    Nicholas Cronin

    Research Analyst at Truist Securities

    Nicholas Cronin is an Equity Research Associate at Truist Securities, specializing in equity research within the financial sector. He has covered companies such as AG Mortgage and works as part of an analyst team providing investment recommendations to institutional clients. Cronin began his tenure at Truist Securities in 2020, contributing to research and analysis after prior professional experience that is not detailed in available records. His credentials include financial research expertise and likely relevant securities licenses required for research associate roles at major broker-dealers.

    Nicholas Cronin's questions to INTEGRAL AD SCIENCE HOLDING (IAS) leadership

    Nicholas Cronin's questions to INTEGRAL AD SCIENCE HOLDING (IAS) leadership • Q2 2025

    Question

    Nicholas Cronin, on behalf of Youssef Squali at Truist Securities, asked for an breakdown of the Q3 guidance by business segment and for commentary on trends in international markets.

    Answer

    CFO Alpana Wegner provided guidance for the second half, expecting Measurement growth in the high single digits, Optimization in the mid-teens, and Publisher growth in the strong double digits. CEO Lisa Utzschneider added that international markets grew 13% in the first half, driven by strong social product adoption in EMEA and APAC, Publica wins, and early progress in China.

    Ask Fintool Equity Research AI

    Nicholas Cronin's questions to Oddity Tech (ODD) leadership

    Nicholas Cronin's questions to Oddity Tech (ODD) leadership • Q3 2024

    Question

    Nicholas Cronin, on for Youssef Squali, questioned the scale of the international expansion opportunity and its timing, and also asked if Brand 3's focus on 'skin and body issues' implies offering GLP-1 drugs.

    Answer

    Co-Founder and CEO Oran Holtzman stated there are currently no plans to offer GLP-1 drugs. Global CFO Lindsay Drucker Mann clarified 'body issues' refers to conditions like eczema, not weight loss. Regarding international expansion, Oran Holtzman described it as a huge long-term opportunity, potentially 50% of the business, but confirmed they are 'slow playing' the expansion and focusing on the U.S. for now, though they are prepared to enter new markets when needed.

    Ask Fintool Equity Research AI